Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

por Italiano, Antoine, Nanda, Shivani, Briggs, Andrew, Garcia-Foncillas, Jesus, Lassen, Ulrik, Vassal, Gilles, Kummar, Shivaani, van Tilburg, Cornelis M., Hong, David S., Laetsch, Theodore W., Keating, Karen, Reeves, John A., Fellous, Marc, Childs, Barrett H., Drilon, Alexander, Hyman, David M.
Publicado 2020

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

por Yang, James C. H., Brose, Marcia S., Castro, Gilberto, Kim, Edward S., Lassen, Ulrik N., Leyvraz, Serge, Pappo, Alberto, López-Ríos, Fernando, Reeves, John A., Fellous, Marc, Penault-Llorca, Frédérique, Rudzinski, Erin R., Tabatabai, Ghazaleh, Vassal, Gilles, Drilon, Alexander, Trent, Jonathan
Publicado 2022

EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

por Goto, Hiroaki, Geoerger, Birgit, DuBois, Steven G, Grilley-Olson, Juneko E, van Tilburg, Cornelis M, Schulte, Johannes, Kang, Hyoung Jin, Tahara, Makoto, Boni, Valentina, Perreault, Sebastien, Capra, Michael, Reeves, John A, Brega, Nicoletta, Childs, Barrett H, Laetsch, Theodore W, Ziegler, David S, Doz, François
Publicado 2020